Copyright
©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Sep 21, 2009; 15(35): 4464-4466
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4464
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4464
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient
Wu-Shiung Huang, Division of Gastroentero-Hepatology, E-DA Hospital/I-Shou University, Kaohsiung 824, Taiwan, China
Chang-Hsu Yang, Department of Pathology and Laboratory medicine, E-DA Hospital/I-Shou University, Kaohsiung 824, Taiwan, China
Author contributions: Huang WS performed the patient care; Huang WS and Yang CH wrote the paper.
Correspondence to: Wu-Shiung Huang, MD, Division of Gastroentero-Hepatology, E-DA Hospital/I-Shou University, Kaohsiung 824, Taiwan, China. e1216860@gmail.com
Telephone: +886-7-6150011 Fax: +886-7-6155352
Received: June 22, 2009
Revised: August 11, 2009
Accepted: August 18, 2009
Published online: September 21, 2009
Revised: August 11, 2009
Accepted: August 18, 2009
Published online: September 21, 2009
Abstract
A 55-year-old male patient with hepatitis B-related liver cirrhosis was found to have advanced hepatocellular carcinoma. His AFP was initially 9828 μg/L and rapidly dropped to 5597 μg/L in ten days after oral sorafenib treatment. However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment. Tumor lysis syndrome was suspected and intensive hemodialysis was performed. Despite intensive hemodialysis and other supportive therapy, he developed multiple organ failure (liver, renal, and respiratory failure) and metabolic acidosis. The patient expired 13 d after admission.